Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-shGrin2a
- Development stage
- Preclinical
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
- Administration
- Intracerebral (experimental; Direct Injection To Hippocampus Or Brain Region)
01
Overview
AAV-shGrin2a is an **experimental gene therapy vector** that uses an **adeno-associated virus (AAV)** to deliver a **short hairpin RNA (shRNA)** targeting the Grin2a gene, which encodes the GluN2A subunit of the N-methyl-D-aspartate receptor (NMDAR), specifically within astrocytes[1]. Grin2a knockdown by AAV-shGrin2a results in reduced expression of astrocytic GluN2A. Preclinical studies have utilized this vector for **astrocyte-specific Grin2a knockdown in the rat hippocampus**, exploring its role in cognitive and synaptic impairments in models of Alzheimer's disease[1]. Mechanistically, AAV-shGrin2a impairs synaptic function and spatial memory, interacting with amyloid-β (Aβ) pathology, and modulating neurotrophin levels (notably nerve growth factor, NGF) and associated pathways (NF-κB, Furin, VAMP3)[1].
- Other names
- adeno-associated virus–short hairpin RNA Grin2aAAV-Grin2a-shRNAAAV-Grin-2a-shRNAAAV-Grin 2a-shRNA
02
Targets
GRIN2A (NMDA receptor subunit 2A)
Beyond the preview
Go deeper on AAV-shGrin2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV-shGrin2a.